Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years

Journal:
Clinical Infectious Diseases
Published:
DOI:
10.1093/cid/ciag058
Affiliations:
13
Authors:
20
Go to article
Institutions Authors Share
GlaxoSmithKline Belgium, Belgium
10.000000
10.000000
 0.50
Momentum Clinical Research - Australia, Australia
1.500000
 0.08
Newtown Clinical Research Centre, South Africa
1.000000
 0.05
Colchester Research Group, Canada
1.000000
 0.05
Reimed, South Africa
1.000000
 0.05
CHU de Québec, UL, Canada
1.000000
 0.05
Diablo Clinical Research, United States of America (USA)
1.000000
 0.05
Shirayurikai Swing Nozaki Clinic, Japan
1.000000
 0.05
Alliance for Multispecialty Research (AMR), United States of America (USA)
1.000000
 0.05
Klinikum Würzburg Mitte gGmbH (KWM), Germany
1.000000
 0.05
The University of Melbourne (UniMelb), Australia
0.500000
 0.03
Interested in Medical Microbiology?